Ischemic preconditioning increases myocardial O-GlcNAc glycosylation

Scandinavian Cardiovascular Journal

Volumn 47, Issue 3, 2013, Pages 168-174

  Jensen, Rebekka Vibjerg ^a,b   Johnsen, Jacob ^a,b   Kristiansen, Steen Buus ^a,b   Zachara, Natasha Elizabeth ^c   Bøtker, Hans Erik ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alloxan; Azaserine; Ischemia reperfusion injury; Ischemic preconditioning; O GlcNAc

Indexed keywords

ALLOXAN; AZASERINE; N ACETYLGLUCOSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GLYCOSYLATION; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HYPOTHESIS; ISCHEMIC PRECONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SENSITIVITY AND SPECIFICITY;

ACETYLGLUCOSAMINE; ALLOXAN; ANIMALS; AZASERINE; DISEASE MODELS, ANIMAL; GLYCOSYLATION; HEMODYNAMICS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; N-ACETYLGLUCOSAMINYLTRANSFERASES; RATS; RATS, WISTAR; RECOVERY OF FUNCTION; TIME FACTORS; UP-REGULATION;

EID: 84878145030     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2012.756984     Document Type: Article

References (18)

1. ., S lawson C, R amirez-Correa G, L agerlof O. C ross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 2011; 80: 825-58.
2. Zachara NE, O ' D onnell N, C heung WD, M ercer JJ, M arth JD, Hart GW. Dynamic O-GlcNAc modifi cation of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J Biol Chem 2004; 279: 30133-42.
3. Murry CE, J ennings RB, R eimer KA. P reconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
4. Jones S P, Z achara N E, N goh G A, H ill B G, T eshima Y, B hatnagar A, et al. Cardioprotection by N-Acetylglucosamine linkage to cellular proteins. Circulation 2008; 117: 1172-82.
5. Lyons S D, S ant M E, C hristopherson R I. C ytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia. J Biol Chem 1990; 265: 11377-81.
6. Suzuki H, K umagai H, T ochikura T. G amma-Glutamyltranspeptidase from Escherichia coli K-12: Purifi cation and properties. J Bacteriol 1986; 168: 1325-31.
7. Lenzen S, M unday R. T hiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin. Biochem Pharmacol 1991; 42: 1385-91.
8. Dorfmueller HC, B orodkin VS, B lair DE, P athak S, N avratilova I, van Aalten DM. Substrate and product analogues as human O-GlcNAc transferase inhibitors. Amino Acids 2011; 40: 781-92.
9. Zachara NE. T he roles of O-linked beta-N-Acetylglucosamine in cardiovascular physiology and disease. Am J Physiol Heart Circ Physiol 2012; 302: H1905-H1918.
10. Liu J, M archase RB, C hatham JC. G lutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. J Mol Cell Cardiol 2007; 42: 177-85.
11. Liu J, M archase R B, C hatham J C. I ncreased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis. Am J Physiol Heart Circ Physiol 2007; 293: H1391-H1399.
12. Konrad RJ, Z hang F, H ale JE, K nierman MD, B ecker GW, Kudlow JE. Alloxan is an inhibitor of the enzyme O-linked N-Acetylglucosamine transferase. Biochem Biophys Res Commun 2002; 293: 207-12.
13. Butkinaree C, P ark K, H art G W. O-linked beta-N-Acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta 2010; 1800: 96-106.
14. Laczy B, M arsh SA, B rocks CA, W ittmann I, C hatham JC. Inhibition of O-GlcNAcase in perfused rat hearts by NAGthiazolines at the time of reperfusion is cardioprotective in an O-GlcNAc-dependent manner. Am J Physiol Heart Circ Physiol 2010; 299: H1715-H1727.
15. Champattanachai V, M archase RB, C hatham JC. G lucosamine protects neonatal cardiomyocytes from ischemiareperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2. Am J Physiol Cell Physiol 2008; 294: C1509-C1520.
16. Ngoh GA, W atson LJ, F acundo HT, D illmann W, J ones SP. Non-canonical glycosyltransferase modulates post-hypoxic cardiac myocyte death and mitochondrial permeability transition. J Mol Cell Cardiol 2008; 45: 313-25.
17. Argaud L, G ateau-Roesch O, C halabreysse L, G omez L, Loufouat J, Thivolet-Bejui F, et al. Preconditioning delays Ca2-induced mitochondrial permeability transition. Cardiovasc Res 2004; 61: 115-22.
18. Javadov SA, C larke S, D as M, G riffi ths EJ, L im KH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003; 549: 513-24.